Evidence for a Functionally Relevant Rocaglamide Binding Site on the eIF4A–RNA Complex
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Translation initiation is an emerging target in oncology and neurobiology indications. Naturally derived and synthetic rocaglamide scaffolds have been used to interrogate this pathway; however, there is uncertainty regarding their precise mechanism(s) of action. We exploited the genetic tractability of yeast to define the primary effect of both a natural and a synthetic rocaglamide in a cellular context and characterized the molecular target using biochemical studies and in silico modeling. Chemogenomic profiling and mutagenesis in yeast identified the eIF (eukaryotic Initiation Factor) 4A helicase homologue as the primary molecular target of rocaglamides and defined a discrete set of residues near the RNA binding motif that confer resistance to both compounds. Three of the eIF4A mutations were characterized regarding their functional consequences on activity and response to rocaglamide inhibition. These data support a model whereby rocaglamides stabilize an eIF4A-RNA interaction to either alter the level and/or impair the activity of the eIF4F complex. Furthermore, in silico modeling supports the annotation of a binding pocket delineated by the RNA substrate and the residues identified from our mutagenesis screen. As expected from the high degree of conservation of the eukaryotic translation pathway, these observations are consistent with previous observations in mammalian model systems. Importantly, we demonstrate that the chemically distinct silvestrol and synthetic rocaglamides share a common mechanism of action, which will be critical for optimization of physiologically stable derivatives. Finally, these data confirm the value of the rocaglamide scaffold for exploring the impact of translational modulation on disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, Silvestrol
Cencic, R., Carrier, M., Galicia-Vázquez, G., Bordeleau, M.-E., Sukarieh, R., Bourdeau, A., Brem, B., Teodoro, J. G., Greger, H., Tremblay, M. L., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005223 · Cited by 302
Self-citationRodrigo, C. M., Cencic, R., Roche, S. P., Pelletier, J., & Porco, J. A. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201263k · Cited by 99
Self-citation
Cited by
Functional 5′ UTR mRNA structures in eukaryotic translation regulation and how to find them
Leppek, K., Das, R., & Barna, M. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.103 · Cited by 949
Targeting the translation machinery in cancer
Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., & Topisirovic, I. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4505 · Cited by 799
Self-citationG3BP–Caprin1–USP10 complexes mediate stress granule condensation and associate with 40S subunits
Kedersha, N., Panas, M. D., Achorn, C. A., Lyons, S., Tisdale, S., Hickman, T., Thomas, M., Lieberman, J., McInerney, G. M., Ivanov, P., et al. (2016) · Journal of Cell Biology · doi:10.1083/jcb.201508028 · Cited by 659
RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer
Wolfe, A. L., Singh, K., Zhong, Y., Drewe, P., Rajasekhar, V. K., Sanghvi, V. R., Mavrakis, K. J., Jiang, M., Roderick, J. E., Van der Meulen, J., et al. (2014) · Nature · doi:10.1038/nature13485 · Cited by 635
Self-citationStress Granules and Processing Bodies in Translational Control
Ivanov, P., Kedersha, N., & Anderson, P. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a032813 · Cited by 496
eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies
Boussemart, L., Malka-Mahieu, H., Girault, I., Allard, D., Hemmingsson, O., Tomasic, G., Thomas, M., Basmadjian, C., Ribeiro, N., Thuaud, F., et al. (2014) · Nature · doi:10.1038/nature13572 · Cited by 371
Targeting the eIF4F Translation Initiation Complex: A Critical Nexus for Cancer Development
Pelletier, J., Graff, J., Ruggero, D., & Sonenberg, N. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2789 · Cited by 367
“The antiproliferative properties of silvestrol appear to be mediated primarily through inhibition of eIF4A because silvestrol-resistant eIF4Amutants can rescue the effect (185).”
BackgroundSelf-citationRocaglates convert DEAD-box protein eIF4A into a sequence-selective translational repressor
Iwasaki, S., Floor, S. N., & Ingolia, N. T. (2016) · Nature · doi:10.1038/nature17978 · Cited by 313
Translational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanoma
Cerezo, M., Guemiri, R., Druillennec, S., Girault, I., Malka-Mahieu, H., Shen, S., Allard, D., Martineau, S., Welsch, C., Agoussi, S., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0217-1 · Cited by 254
Rubio, C. A., Weisburd, B., Holderfield, M., Arias, C., Fang, E., DeRisi, J. L., & Fanidi, A. (2014) · Genome Biology · doi:10.1186/s13059-014-0476-1 · Cited by 200
“This compound has been shown to selectively target the RNA helicase activity of eIF4A both in vitro and in vivo, thereby impairing translation initiation [21,22], and is known to have robust anti-cancer effects [23,24].”
BackgroundErnst, J. T., Thompson, P. A., Nilewski, C., Sprengeler, P. A., Sperry, S., Packard, G., Michels, T., Xiang, A., Tran, C., Wegerski, C. J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00182 · Cited by 150
eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma
Chan, K., Robert, F., Oertlin, C., Kapeller-Libermann, D., Avizonis, D., Gutierrez, J., Handly-Santana, A., Doubrovin, M., Park, J., Schoepfer, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13086-5 · Cited by 106
Self-citationMolecular Pathways: The eIF4F Translation Initiation Complex—New Opportunities for Cancer Treatment
Malka-Mahieu, H., Newman, M., Désaubry, L., Robert, C., & Vagner, S. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2362 · Cited by 105
“The direct interaction with eIF4A was shown using affinity chromatography (37) and chemogenomic profiling in yeast (38).”
MethodDecatransin, a novel natural product inhibiting protein translocation at the Sec61/SecY translocon
Junne, T., Wong, J., Studer, C., Aust, T., Bauer, B. W., Beibel, M., Bhullar, B., Bruccoleri, R., Eichenberger, J., Estoppey, D., et al. (2015) · Journal of Cell Science · doi:10.1242/jcs.165746 · Cited by 67
“…experiments in fungi and mammalian cells have revealed that there is a bias towards chromosomal aberrations and SNPs in pleiotropic drug-resistance genes if spontaneous mutants are selected and sequenced (Nyfeler et al., 2012; Richie et al., 2013; Sadlish et al., 2013; Shimada et al., 2013).”
BackgroundSelf-citationThompson, P. A., Eam, B., Young, N. P., Fish, S., Chen, J., Barrera, M., Howard, H., Sung, E., Parra, A., Staunton, J., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0973 · Cited by 50
Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
Singh, K., Lin, J., Lecomte, N., Mohan, P., Gokce, A., Sanghvi, V. R., Jiang, M., Grbovic-Huezo, O., Burčul, A., Stark, S. G., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2929 · Cited by 39
“Importantly, the natural compound silvestrol binds eIF4A with nanomolar affinity and disables its RNA unwinding activity (7-10).”
BackgroundZhao, N., Kabotyanski, E. B., Saltzman, A. B., Malovannaya, A., Yuan, X., Reineke, L. C., Lieu, N., Gao, Y., Pedroza, D. A., Calderon, S. J., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci172503 · Cited by 30
Chang, L.-S., Oblinger, J. L., Burns, S. S., Huang, J., Anderson, L. W., Hollingshead, M. G., Shen, R., Pan, L., Agarwal, G., Ren, Y., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0809 · Cited by 22
“Like silvestrol, rocaglamides exert their potent growth-inhibitory and antitumor activities mainly through inhibition of eIF4A and protein translation (43, 44).”
BackgroundSelf-citationPost-transcriptional control of antifungal resistance in human fungal pathogens
Sharma, C., & Kadosh, D. (2023) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2022.2080527 · Cited by 6
“…that rocaglate compounds, which specifically inhibit translation initiation in mammalian cells and in S. cerevisiae through interaction with eIF4A (Sadlish et al. 2013; Iwasaki et al. 2016, 2019; Shen and Pelletier 2020), cause hyperacidification and fragmentation of the vacuolar compartment,…”
Background
Metadata
- Authors
- Sadlish, H., Galicia-Vazquez, G., Paris, C. G., Aust, T., Bhullar, B., Chang, L., Helliwell, S. B., Hoepfner, D., Knapp, B., Riedl, R., Roggo, S., Schuierer, S., Studer, C., Porco, J. A., Pelletier, J., & Movva, N. R.
- Venue
- ACS Chemical Biology
- Publisher
- American Chemical Society (ACS)
- Published
- 2013-05-07
- Volume
- 8
- Issue
- 7
- Pages
- 1519-1527
- ISSN
- 1554-8929 (ISSN-L)
- 1554-8937
- OpenAlex
- W2021708038
- Cited by
- 127
- References
- 2
- FWCI
- 4.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.